Creating a genetic database аs a strategic challenge of modern medical researches by Vesnina, L. et al.
Проблеми екології та медицини   
 8 
ENGLISH VERSION: CREATING A GENETIC DATABASE  
AS A STRATEGIC CHALLENGE OF MODERN MEDICAL RESEARCHES* 
Vesnina L.,Kaidashev I. 
Research Institute for Genetics and Immunological Grounds of Pathology and  Pharmacogenetics of Higher State Educational Establishment of 
Ukraine ―Ukrainian Medical Stomatological Academy‖, Poltava, Ukraine  
Research Institute for Genetics and Immunological Grounds of Pathology and Pharmacogenetics among the first institu-
tions in Ukraine had created a genetic database growing for the last  few years. The creation of this database is neces-
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Rapid development of molecular and cell biology has 
significantly expanded our understanding of biochemical, 
physiological, molecular, and other processes in the 
healthy human body and allowed us to draw conclusions 
regarding subtle pathogenic mechanisms of particular 
clinical symptoms and diseases. World medical expe-
rience shows that the achievement in human genetics is 
no less important, and its potential could be fully realized 
in the collaboration of geneticists and physicians pro-
vided that the bioethical and deontological research 
norms will be met. 
The need of medical diagnosis and genetic counseling 
of not only rare genetic diseases associated with severe 
disorders and complications but also the most common dis-
eases such as diabetes, coronary heart disease, arterial 
hypertension, and atherosclerosis is currently a significant 
problem of practical medicine, that‘s why the creation of ge-
netic database was assigned as a primary task. In the long-
er term, database and expert systems integration will signifi-
cantly enhance the ability of doctors and increase the effec-
tiveness of diagnostic decisions. Developing effective pre-
vention programs becomes possible on the basis of genetic 
monitoring data; the use of such programs will prevent the 
development of diseases, maintain health and prolong 
people‘s lives, generally having a significant positive eco-
nomic impact for society. 
Research Institute for Genetics and Immunological 
Grounds of Pathology and Pharmacogenetics among the 
first institutions in Ukraine had created a genetic data-
base that is growing for the last few years. This database 
is necessary to monitor such common pathological condi-
tions as metabolic syndrome, diabetes, arterial hyperten-
sion, coronary heart disease, allergic inflammation, uro-
genital infections, pathologies of immune and endocrine 
systems, and connective tissue pathologies. Despite dif-
ferent clinical manifestations, these diseases do not have 
completely certain aspects of etiology and pathogenesis 
making it difficult and sometimes making preventive and 
therapeutic measures quite ineffective. 
Collecting samples was begun within ―Diabetes‖, 
―Prevention and treatment of arterial hypertension in 
Ukraine‖, and ―Prevention and treatment of dental dis-
eases‖ state programs. 
Database creation had been conducted in accor-
dance with the subjects of scientific researches that were 
funded by government ―Study of switching of immunoglo-
bulin synthesis in patients with bronchial asthma for de-
veloping new methods of etiologic and pathogenetic 
therapy‖, № SR 0106U003241; ―Development of me-
thods for the prevention and treatment of diseases result-
ing from metabolic syndrome with drugs that stimulate 
the receptors, activating РРАR-, by improving diagnostic 
criteria‖, № SR 0107U01555; ―Defining the role of poly-
morphisms in Toll-like receptors in the development of 
immune mediated diseases‖, № SR 0109U001629; 
―Study of genetic features of allergic inflammation and 
target organs formation‖, № SR 0110U003032; ―Complex 
research of genetically determined characteristics of NF-
kB-mediated signal transduction that specifies the devel-
opment of chronic systemic inflammation in patients with 
metabolic syndrome and type 2 diabetes‖, № SR 
0111U001774; ―The role of inflammatory diseases of 
teeth-jaw apparatus in the development of diseases as-
sociated with systemic inflammation‖, № SR 
0112U001538. 
The purpose of creating genetic database of 
Ukraine‘s population representatives had become an ur-
gent need to monitor and control the most common infec-
tious and non-infectious diseases rate among Ukrainians, 
to define and substantiate the leading role of genetic fac-
tors contributing to their development, and, based on this, 
to develop targeted programs for early diagnosis and 
treatment, risk groups formation and predicting the nature 
and rate of progression of the pathological process. 
Materials and methods 
We received an approval of Bioethics Commission of 
Higher State Educational Establishment of Ukraine 
―Ukrainian Medical Stomatological Academy‖ to conduct 
the study. According to the standards of Good Laboratory 
Practice (GLP) and Good Clinical Practice (GCP) all pa-
tients signed an informed consent, and a voluntary con-
sent was received from parents of children to the partici-
pation in the survey. 
Biological materials (blood, serum, dried blood spots, 
epithelial scraping) were obtaining in the morning on an 
empty stomach using standard methods for storage or 
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immediate examination. Samples had been stored for a 
long time using a low-temperature refrigeration (from -  
24º to -70º C). 
During patients‘ registration, basic parameters were 
taken into account: passport information, sex, age, estab-
lished diagnosis, survey results. Primary registration has 
been made in the current registration journals, and then 
the patient data and survey results were put into a Micro-
soft Office Excel 2007 database. Statistical analysis of 
the research results had been conducted using STATIS-
TICA for Windows 7.0 (StatSoft Inc, USA). 
Results and discussion 
Main areas of study were identified from the beginning of 
genetic database creation: monitoring survey of relatively 
healthy persons (citizens of the Poltava region), patients with 
urogenital diseases; persons who were initially examined or 
treated by an endocrinologist for thyroid diseases; patients 
with signs of allergic inflammation; patients with disorder of 
lipid metabolism and features of metabolic syndrome; pa-
tients with connective tissue diseases. 
Below we provide a brief overview of some samples 
and examples of their practical use. 
Population control group was created in the first 
phase of research and consisted of relatively healthy 
persons of different age and sex (Table 1). For the cohort 
survey of population control group, an observation card in 
a form of questionnaire was pre-designed, each surveyed 
person should provide there detailed data on age, sex, 
nationality, social, occupational, genetic, epidemiological, 
allergy, therapeutic, and surgical anamneses, clinical sta-
tus data at the time of inspection and objective data re-
garding various organs and systems. Later, card was 
supplemented with laboratory research data, and all in-
formation was fixed electronically. 
Initially, population control group included 114 rela-
tively healthy persons aged from 19 to 62 years. While 
forming, population control group was supplemented with 
185 examples of citizens of Poltava region with different 
age and sex, who were considered as relatively healthy 
persons at the time of the survey. Group of people with 
urogenital diseases (chlamydia, ureaplasmosis, tricho-
moniasis, gardnerellosis, mycoplasmosis, and bacterial 
vaginosis) was formed of 156 patients. Overall, the total 
number of surveyed persons was 455 patients. 
How can we use this material? Precisely using named 
samples, the prevalence of single nucleotide polymor-
phisms of TLR2 gene Arg753Gln with replacement of G 
to A at position 2258 (rs5743708), and TLR4 genes 
Asp299Gly with replacement of A to G at position 896 
(rs4986790) and Thr399Ile with replacement of C to T at 
position 1196 (rs4986791) was investigated for the first 
time in Ukraine‘s population among healthy persons of 
Poltava region‘s population and among patients with 
common urogenital diseases [1].  
We studied 299 persons from population control 
group (relatively healthy), balanced by sex, aged from 19 
to 62 years, and 156 patients of different age and sex 
with urogenital infections. Study material was epithelial 
cells scraped from the urethra or cervix that were ob-
tained via special sterile disposable urogenital probes. 
We found a reliable correlation between the presence 
of mutant A allele in a genotype (GA and AA genotypes) 
of TLR2 gene and mutant G allele (AG and GG geno-
types) of TLR4 gene and the increased risk of infection 
with common urogenital infections (χ
2
=7.99; OR=2.01; 
CI=1.26-3.21; р=0.0047) that‘s why these single nucleo-
tide polymorphisms can be considered as an additional 
prognostic indicator in pathogenetic studies. 
Since 2008, we are collecting samples of patients 
with allergic inflammation (Table 1). Criteria for inclusion 
in the group are the signs and/or a clearly established 
diagnosis of allergic inflammation according to ICD-10 
(bronchial asthma, allergic rhinitis, atopic dermatitis, urti-
caria). The number of samples is 620, creation of data-
base is ongoing. Age range is from 6 months to 84 years, 
an average age of children is 4.3 ± 3.5 years. 
The role of polymorphisms of the genes encoding 
TLR2 (rs5743708) and TLR4 (rs4986790, rs4986791) in 
increasing production of specific immunoglobulin E (IgE) 
and the development of allergic inflammation was deter-
mined [5]. We conducted genotyping of these three sin-
gle nucleotide polymorphisms in the control group and in 
patients with allergic inflammation. Dry blood spots were 
used as biological material. 
Group of patients consisted of 38 persons with aller-
gic inflammations (19 persons with atopic asthma, 13 
ones with atopic dermatitis, and 6 patients with atopic 
rhinitis). The selection criterion was the high level of al-
lergen-specific IgE (from 3.5 to 100 kU/l) to at least one 
of allergens. To verify the IgE-dependent allergic inflam-
mations, we studied specific IgE to 20 most important al-
lergens [5]. Population control group consisting of 95 
persons with a lack of allergic inflammation in history was 
used as a control. 
As a study result, we established the relationship be-
tween TLR2 (rs5743708) and TLR4 (rs4986790) poly-
morphisms with elevated level of specific IgE production 
in patients with allergic inflammations that‘s why these 
single nucleotide replacements can be considered as an 
additional prognostic characteristic of individual suscepti-
bility to these diseases. 
We formed a separate group of 140 patients with al-
lergic diseases (bronchial asthma, allergic rhinitis, atopic 
dermatitis), in whom were determined polymorphic variants 
of TLR2 and TLR4 genes and indicators of the immune sys-
tem state [7, 9]. The study of polymorphic variants of TLR4 
896A/G (rs4986790), 1196C/T (rs4986791) gene and TLR2 
2258G/A (rs5743708) gene showed that exactly TLR4 gene 
896A/G polymorphism causes the severity and complicated 
course of atopic dermatitis in children [8]. 
We are creating a database of patients who contacted 
Research Institute for Genetics and Immunological 
Grounds of Pathology and Pharmacogenetics about 
screening for thyroid disease. 2547 samples amount the 
most significant part of the whole database now. Age 
range is from 20 to 80 years. 
Within the state ―Program of prevention and treatment 
of arterial hypertension in Ukraine‖ in cooperation with 
NRC ―M. D. Strazhesko Institute of Cardiology‖ of NAMS 
of Ukraine, the direction with the purpose to study the pa-
thogenesis of metabolic syndrome (MS) and chronic sys-
temic inflammation was shaped. 
Citizens of Poltava aged from 18 to 64 years were 
surveyed (896 persons in total: 579 women and 317 
men). In Cherkasy 388 people were surveyed (222 wom-
en aged from 18 to 63 years and 166 men aged from 19 
to 64 years) (Table 1). 
Table 1 
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Groups 
Number of 
samples 
Sex Age 
Laboratory Methods 
M F M F 
1 2 3 4 5 6 7 
Relatively healthy per-
sons 
114 47 67 
Aged 18-62 
years 
Aged 18-62 
years 
lipid metabolism, glucose, cytokines,  
polymorphisms 
2258G/А TLR2 (rs5743708) 
896A/G TLR4 (rs4986790) 
Patients with urogenital 
diseases 
341 195 146 
Aged 20 - 
80 years  
Aged 20 - 
80 years 
polymorphisms  
2258G/А TLR2 (rs5743708) 
896A/G TLR4 (rs4986790) 
1196С/Т TLR4 (rs4986791) 
Patients with thyroid 
diseases 
2547 
101
8 
152
9 
Aged 20 - 
80 years 
Aged 20 - 
80 years 
Т3, Т4, TSH, Ab to TPO, Ab to TSH 
Patients with allergic 
diseases 
620   
Aged 6 
months- 84 
years 
Aged 6 
months- 84 
years 
Allergen-specific IgE 
Patients with bronchial 
asthma 
45 18 27 
Aged 18 – 
70 years 
Aged 18 - 
70 years 
IgE, IL-4, IL-10, CD4, CD25, Foxp3  
polymorphisms  
2258G/А TLR2 (rs5743708),  
896A/G TLR4 (rs4986790) 
allergic rhinitis 45 23 22 
Aged 19 - 
65 years 
Aged 19 - 
65 years 
CD4
+
, CD4
+
/25
+
, CD4
+
/25
+
/Foxp3  
polymorphism  
896A/G TLR4 (rs4986790) 
atopic dermatitis 50 24 26 
Aged 2 -  
7 years 
Aged 2 -  
7 years 
CD3, CD4, CD8, CD16, CD20, IgA, IgM, 
IgG, IgE, CIC 
polymorphisms  
2258G/А TLR2 (rs5743708),  
896A/G TLR4 (rs4986790),  
1196C/T TLR4 (rs4986791) 
Patients with dyslipide-
mia 
199 95 104 
Aged 20 - 
80 years 
Aged 20 - 
80 years 
lipid metabolism, ceruloplasmin, polymor-
phism PPARγ (Pro12Ala) 
Patients with metabolic 
syndrome  
1441 567 874 
Aged 18 - 
75 years 
Aged 18 - 
75 years 
lipid metabolism, glucose, glycosylated 
hemoglobin, cytokines, polymorphisms  
PPARγ (Pro12Ala),  
LPL (С→Т, intron 6);  
LPDR (С→Т, intron 15);  
MTHFR (Ala222Val) 
Patients with combined 
pathology: metabolic 
syndrome, arterial 
hypertension  
106 106 - 
Aged 20 - 
80 years 
Aged 20 - 
80 years 
polymorphisms  
AGTR1 (A1166C); 
ACE (Alu Ins/Del I>D) 
Patients with combined 
pathology: metabolic 
syndrome, coronary 
heart disease, bronchial 
asthma, endothelial 
dysfunction 
102 69 33 
Aged 40 - 
75 years 
Aged 40 - 
75 years 
lipid metabolism, glucose, cytokines, 
CRP, ICAM–1,VCAM–1 
polymorphism PPARγ (Pro12Ala), 
expression NF-kB1, NF-kB2 
Study on the genes of 
structural proteins 
159 72 87 
Aged 20 - 
95 years 
Aged 20 - 
95 years 
polymorphisms 
MMP12 (A-82G); 
MMP20 (g.16250T>A); 
KLK (g.2142G>A); 
ELN (g28197 A>G) 
Patients with connective 
tissue disorders 
53 22 31 
Aged 20 - 
80 years 
Aged 20 - 
80 years 
Screening panel: Ro/SS-A, La/SS-B, Scl-
70, PM-Scl-100, Jo-1, PCNA, dsDNA, rib.P-
Protein, CENP-В, AMA-M2, PR3, MPO, 
TPO, tireohlobulin 
 
Using the data of this line of research, the prevalence 
of lipoprotein lipase (LPL) gene PvuII polymorphism and 
the connection with arterial hypertension development 
were investigated in Cherkasy population [12]. 
85 men aged 19-66 years were selected among the 
patients of Cherkasy 1st clinical hospital to study the po-
lymorphism of LPL gene and divided into two groups. 
Control group (n=47) consisted of persons with normal 
blood pressure <140/90 mmHg, main group (n=38) in-
cluded patients with the level of blood pressure ≥140/90 
mmHg or persons with an arterial hypertension in the 
anamnesis. 
Distribution of LPL polymorphisms in a population 
control group and in a group of men with arterial hyper-
tension in Cherkasy population was carried out for the 
first time. In the population of control group, genotype 
frequencies were as follows: СС – 29.79% СТ – 51.06%, 
and TT – 19.15%; allele frequencies were: C – 55.32% 
and T – 44.68%. In men with hypertension, frequency of 
genotypes and alleles of the LPL gene was not signifi-
cantly different from the population control group: СС – 
34.21%, CT – 47.37%, and TT – 18.42%; C – 57.9% and 
T – 44.1% for alleles. 
Relationship between PvuII polymorphism in the LPL 
gene and the development of arterial hypertension has 
not been established. But the findings suggest that it 
would be appropriate to study this polymorphism in pa-
tients with clearly defined features of metabolic syn-
drome. 
Within the determination of genetic risk factors for es-
sential hypertension, we studied the distribution of poly-
morphisms of angiotensin II type 1 receptor AGTR1 
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(A1166C) [4]. In healthy persons (n=100), the frequen-
cies of genotypes and alleles were: АА – 51%, AC – 
34%, and СС – 15%; А – 68% and C – 32% for alleles. 
An overwhelming prevalence of C allele and CC geno-
type in healthy people in the Ukrainian population was 
assumed. Genotype frequencies in patients with essen-
tial hypertension (106 persons) were: AA – 22.85% and 
AC – 51.9%; and allele frequencies were: CC – 25.3 %; 
A – 48.7% and C – 51.3%. It was concluded that the de-
velopment of essential hypertension is associated with 
the presence of C allele and its homozygous variant, the 
severity and complications of hypertension depend on 
the presence of this allele in the genotype. Ukrainian 
population has a specific distribution of polymorphisms of 
angiotensin II type 1 receptor with a predominance of 
C1166 allele and CC genotype that is a risk factor for es-
sential hypertension. 
In general, it should be noted that while collecting 
samples of this trend, the need arose for division into 
groups allowing to more thoroughly investigate patients 
and focus on a particular pathology. Thus, we managed 
to investigate some polymorphic variants of a number of 
genes: angiotensin II type 1 AGTR1 (A1166C), angioten-
sin-converting enzyme (ACE) (Alu Ins / Del I> D), peroxi-
some proliferator-activated receptor (PPAR)-γ 
(Pro12Ala), lipoprotein lipase (LPL) (C → T, intron 6), li-
poprotein receptor (LPDR) (C → T, intron 15) [2, 3]. Ma-
terial is currently being collected to continue genetic stu-
dies of the pathogenesis of metabolic syndrome (Table 
1). 
The importance of using database to develop effec-
tive advanced schemes of therapy should be noted. 
Thus, while studying pharmacogenetic characteristics of 
metformin action in patients with coronary artery disease 
on the background of metabolic syndrome and type 2 di-
abetes taking into account Pro12Ala polymorphism of the 
PPAR-γ2 gene, we defined its high therapeutic efficacy in 
patients with coronary artery disease on the background 
of type 2 diabetes who have the Pro/Pro genotype, signif-
icantly enabling individualized therapy [6]. 
Sampling for further study of the role genetic poly-
morphisms of structural proteins genes in inflammatory 
and degenerative processes of organs and tissues is an 
interesting and promising trend. Matrix metalloproteinas-
es (MMP12 (A-82G); MMP20 (g.16250T> A)), kallikrein 
(KLK (g.2142G> A)), elastin (ELN (g28197 A> G)) are 
among them to name a few (Table 1) [10]. 
Thus, we determined polymorphism of kallikrein 4 
(KLK4) gene in exon 4 g.2142 G>A (AF228497) in 72 pa-
tients with excessive tooth wear of I-III degree (30 men, 
42 women, aged 20-62 years) [11]. 
It was shown that more serious signs of excessive 
tooth wear are observed namely in carriers of A allele of 
g.2142 G>A polymorphism of KLK4 gene. The obtained 
data confirm the relationship between the presence of 
polymorphic A allele of KLK4 gene with excessive tooth 
wear. These data allow us to consider this polymorphism 
as an additional prognostic indicator of excessive loss of 
dental hard tissues, and the detection of mutant A allele 
of KLK4 gene enables purposefully carrying out preven-
tion and treatment of patients with excessive tooth wear. 
Data on patients with autoimmune connective tissue 
diseases such as scleroderma, rheumatoid arthritis, vas-
culitis, who were examined in the Research Institute for 
Genetics and Immunological Grounds of Pathology and 
Pharmacogenetics by using modern screening panels, 
providing sighting diagnosis of disease and significantly 
improving the effectiveness of therapy, are of great prac-
tical significance (Table 1). 
Work on creating genetic database continues. Such 
work is rather tedious, demanding, but the possibility of 
its practical use and value is difficult to estimate. We 
mentioned only some directions of data accumulation 
and some examples of their use in clinical practice. It 
should be noted, data on the prevalence of polymorphic 
variants of genes in the Ukrainian population are sup-
plemented first of all step by step, theoretical foundation 
of medical genetics is being created, and certain levels of 
pathogenetic mechanisms are defining. 
The creation of genetic databases will allow intensify-
ing significantly medical studies. Systematization and 
registration of respondents forming groups of patients 
and population control group is going on using electronic 
documents that facilitates quick search, working with 
large data sets, adding additional inspection data, and 
research data in dynamics. The possibilities of using 
modern methods of statistical data processing, thorough 
analysis of frequency of distribution of polymorphic va-
riants of genes in the general population and in selected 
groups of respondents also increase. 
Standardization of methodical approaches to finding 
genetic markers of the most common diseases allows 
using modern certified reagents, test systems, and po-
werful scientific equipment. These factors significantly 
facilitate a scientific cooperation and interest in conduct-
ing joint researches on the collection and processing of 
data not only between research institutions, but also clin-
ical genetics centers. 
Creation of genetic monitoring system and identifying 
genetic markers of susceptibility to infectious agents and 
propensity to noninfectious origin diseases development 
will allow monitoring the level of morbidity in Ukraine by 
predicting the risk of developing certain pathological con-
ditions, the nature and progression rate of pathological 
process, the formation of risk groups of possible morbidi-
ty since the childhood, and using effective prevention 
technologies. Development of targeted programs for ear-
ly diagnosis and treatment taking into account a genetic 
predisposition will reduce the direct economic costs of 
medication, duration of outpatient and inpatient treatment 
by pharmacogenetic selection of main groups of drugs, 
decrease the incidence of complications and mortality 
level and will promote the introduction of individual strat-
egies of preventive measures and improving health. 
Ultimately, the prime importance of genetic databases 
is in the strategic direction of determining genetic mark-
ers of a number of common diseases that will be the ba-
sis for the conservation and sustainability of sanitary-
epidemiological welfare of Ukraine. In our opinion, this 
achievement will bring a new level of basic and applied 
genetic researches in Ukraine and will deservedly contri-
bute to increase the authority of our state among the 
scientific community. 
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